KLDO
Kaleido Biosciences, Inc.
OTCHealthcareBiotechnologyUS
Company Profile
CEO
Mark A. Wingertzahn
IPO Date
2019-02-28
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
Kaleido Biosciences, Inc.
CEO
Mark A. Wingertzahn
IPO Date
2019-02-28
Sector
Healthcare
Industry
Biotechnology
Exchange
OTC
Country
US
| 250,000 |
| $0.00 |
| 18 Jan 2022 | Korn Jerald | COO & General Counsel | A-Award | Acquired | 45,240 | $0.00 |
| 18 Jan 2022 | Duke William E. | Chief Financial Officer | A-Award | Acquired | 125,000 | $0.00 |
| 18 Jan 2022 | Duke William E. | Chief Financial Officer | A-Award | Acquired | 44,990 | $0.00 |
| 18 Jan 2022 | Menichella Daniel L | director, officer: Chief Executive Officer | A-Award | Acquired | 250,000 | $0.00 |
| 18 Jan 2022 | Menichella Daniel L | director, officer: Chief Executive Officer | A-Award | Acquired | 70,200 | $0.00 |
| 2 Sept 2021 | Korn Jerald | General Counsel | A-Award | Acquired | 100,000 | $6.29 |
| 2 Sept 2021 | Duke William E. | Chief Financial Officer | A-Award | Acquired | 60,000 | $6.29 |
| 2 Sept 2021 | Menichella Daniel L | director, officer: Chief Executive Officer | A-Award | Acquired | 110,000 | $6.29 |